Top Tweets for #ChildGHD
Lumos Pharma is excited to be exhibiting at #ENDO2025 in San Francisco (Booth 709) and to share four #LUM-201 posters educating global endocrinologists about our investigational oral GH secretagogue being studied in #childGHD and #bodycomposition
Our #EmployeeSpotlight this month is Chris Smith, Senior Director, Clinical Operations. He has played a pivotal role in advancing our oral therapy for #ChildGHD into the clinic. He embodies our team's commitment to improving the lives of those with #RareDisease. Thank you, Chris!
Members of the Lumos Pharma team had an amazing time at #ENDO2024! It was an honor to present clinical data on our oral lead candidate for #ChildGHD & connect with many brilliant minds in the field of #endocrinology. The future of endocrine health is brighter than ever. $LUMO
This @GoHealio article from @EndocrineToday highlights data presented at #PedsENDO2024 showing the potential of our oral therapy for #ChildGHD. Read now: https://t.co/MrK6t3G9TD
💊A once-daily oral medication performed similarly to recombinant human GH for children with moderate pediatric GH deficiency, according to data presented at the @PedsEndoSociety annual meeting.
Learn more 👇
@endodocdauber @ChildrensNatl
https://t.co/cpcECIz65n
We will be attending the @PedsEndoSociety Annual Meeting starting today, where Dr. Andrew Dauber will present on LUM-201, our oral therapeutic candidate for #ChildGHD. Learn more: https://t.co/wFZMTPbtQ5 $LUMO
#ICYMI, we are presenting clinical data on our oral therapeutic candidate, LUM-201 in #ChildGHD at @PedsEndoSociety Annual Meeting, the 10th Growth Hormone Research Society meeting & @ESEndocrinology European Congress of Endocrinology 2024. More here: https://t.co/7J4MAZWxDj
We asked our incredible team what #RareDiseaseDay means to them, and the overwhelming response spoke volumes. Our employees share a unified sentiment on why Lumos Pharma is committed to finding a treatment for those with #ChildGHD. Stay tuned for more!
Our Chief Medical Officer, Pisit (Duke) Pitukcheewanont, shared with @PatientWorthy his pediatric endocrinology journey, the evolution of growth hormone deficiency treatments and his passion advancing an oral candidate for #ChildGHD. More here: https://t.co/8EcbXcu0XS
Tomorrow during the @TheEndoSociety Annual Meeting, Dr. Cassorla and Dr. Tansey will be presenting on our interim data for idiopathic pediatric growth hormone deficiency (#ChildGHD). Learn more about the abstracts here: https://t.co/PEZJA1jtWI #ENDO2023 #OraGrowthTrials
Ahead of #ENDO2023, hear from a leading pediatric endocrinologist about the potential for an oral candidate alternative for the treatment of idiopathic pediatric growth hormone deficiency (#ChildGHD) in this @Endocrine_News feature: https://t.co/iXZSF0Wt8K
On June 21, we will host a virtual KOL webinar featuring Drs. Fernando Cassorla and Michael Tansey, who will review interim data presented at ENDO 2023 on our investigative oral treatment for pediatric growth hormone deficiency (#ChildGHD). Register here: https://t.co/wPJVY4HGbd
On June 17, our interim data for idiopathic pediatric growth hormone deficiency (#ChildGHD) will be reviewed in two oral presentations at the @TheEndoSociety Annual Meeting. More info here: https://t.co/h0JCSY2uey #ENDO2023
Today, we announced that interim data from our two ongoing Phase 2 trials will be reviewed in oral presentations at #ENDO2023 and discussed during a KOL webinar on June 21! To learn more & register, visit: https://t.co/b0rUXB7ZbG $LUMO #ChildGHD #PediatricGrowthHormoneDeficiency
Catch up on our interim phase 2 data for our lead candidate in idiopathic pediatric growth hormone deficiency (#ChildGHD) in this @GoHealio article: https://t.co/cPXVCES0kv #OraGrowtHTrials
Our CEO, Rick Hawkins, and President/CSO, John McKew, PhD, recently spoke with @Pharmashot about our oral candidate to treat idiopathic pediatric growth hormone deficiency (#ChildGHD) & interim data from our Phase 2 #OraGrowtHTrials. Conversation here: https://t.co/yDn9aS9Wtg
We’re looking forward to our oral presentation on Phase 2 OraGrowtH210 Trial and our poster presentation on PK/PD OraGrowtH212 Trial at the @PedsEndoSociety Annual Meeting May 5-8. Read more here: https://t.co/GRXMOM6Bba
#PedsEndo2023 #ChildGHD $LUMO
Catch our CEO, Rick Hawkins, in conversation with @dslevine on the RARECast podcast about our efforts to advance an oral alternative for idiopathic #ChildGHD and our commitment to support patients with #RareDiseases. Full interview here: https://t.co/4iLfGPzeYf
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.6M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers